CBD for endometriosis: does it help and how to use it to reduce pain

Endometriosis affects an estimated 10% women of reproductive age—in Poland, this translates to over 1.5 million patients. Diagnosis takes an average of 7–10 years from the first symptoms, and pelvic pain, dysmenorrhea, and pain during intercourse are often downplayed or misdiagnosed for years. Women with endometriosis are increasingly seeking complements to conventional treatment—and CBD regularly appears in this context. Is there a scientific basis for this? The data is promising, though preliminary. This article examines the mechanisms, research data, and practical aspects of use—without promises of cure, but with a reliable assessment of its potential.

KEY INFORMATION
• A survey of 484 women with endometriosis found that cannabinoids were rated as one of the top 3 non-hormonal methods for pain relief (Armour et al., Journal of Obstetrics and Gynaecology Canada, 2019).
• CB1 and CB2 receptors are expressed in endometriotic tissue – and at higher concentrations than in healthy endometrium (Sanchez et al., PLOS ONE, 2016).
• CBD works on pelvic pain by inhibiting TRPV1, CB2 receptors and lowering IL-8, a key inflammatory mediator in endometriosis.
• ESHRE (European Society of Human Reproduction and Embryology) in its 2022 guidelines does not recommend cannabinoids as first-line therapy, but considers the topic to require further research.
• CBD does not cure endometriosis – it may support pain management as an adjunct to medical therapy.

Why Endometriosis Hurts - The Pain Mechanism and the Role of the ECS

Endometriosis is a condition in which tissue similar to the lining of the uterus (endometrium) grows outside the uterine cavity—on the ovaries, fallopian tubes, peritoneum, intestines, and other organs. This ectopic tissue responds to the hormonal cycle just like the endometrium itself: it grows, bleeds, and becomes inflamed. However, the blood cannot drain away, leading to chronic inflammation, scarring, adhesions, and severe pain.

Endometriosis pain has several components: inflammatory (cytokines, prostaglandins), neuropathic (peripheral nerves and central sensitization), and nociceptive (direct tissue irritation). Sanchez et al. (PLOS ONE, 2016) showed that endometriotic tissue expresses CB1 and CB2 receptors at significantly higher levels than healthy endometrium—suggesting that the endocannabinoid system plays a regulatory role in this disease. Furthermore, the study found that anandamide (an endogenous CB2 receptor agonist) is elevated in endometriotic tissue, which may be a compensatory mechanism by the body attempting to suppress its own inflammation and pain.

This finding is important for understanding CBD's potential: if the endocannabinoid system is biologically involved in endometriosis—and the data suggest it is—then intervention through this system makes biological sense.

What does the research say – cannabidiol and endometriosis pain?

Head-to-head randomized clinical trials evaluating CBD in women with endometriosis are still lacking. However, the available data are compelling enough to take the topic seriously rather than dismiss it as "unproven.".

The key study is a cross-sectional survey Armor et al. (Journal of Obstetrics and Gynecology Canada, 2019), which included 484 women with endometriosis and evaluated various self-management methods. Cannabinoids (both CBD and THC) were rated by participants as highly effective for pelvic pain, dysmenorrhea, and pain during intercourse—and ranked higher than NSAIDs, diet, and exercise in terms of perceived effectiveness for pain. Yes, it's a survey, not an RCT—but 484 women with a confirmed diagnosis provides an important qualitative signal.

Mechanistically: CBD inhibits the TRPV1 receptor (a vanilloid receptor responsible for nociception and inflammatory pain)—which is overexpressed in pelvic pain tissues. Study Lapointe et al. (Biology of Reproduction, 2013) showed that TRPV1 is present in endometriotic tissue and that its activation increases pain, while its blockade reduces it. CBD, as a TRPV1 blocker, therefore has a direct biological pathway to relieving endometriosis pain.

Endometriosis and the endocannabinoid system - new discoveries

Recent research suggests that disruptions in the endocannabinoid system may not only accompany endometriosis but also contribute to its pathogenesis. Dmitrieva et al. (Neuroreport, 2010) found that women with endometriosis have lower levels of N-palmitolyl-ethanolamine (PEA)—an endogenous peptide with CBD-like effects—compared to women without the disease. Low PEA is associated with greater pain sensitivity, which may explain why pain in endometriosis is often disproportionately severe relative to the extent of the anatomical changes.

CBD supplementation may support the ECS through two mechanisms: a direct effect on CB2 and TRPV1 in endometriotic tissue and inhibition of the enzyme FAAH, which degrades anandamide and PEA. By increasing the body's own endocannabinoid levels, CBD may help restore the "pain inhibition" that is impaired in women with endometriosis. This is a mechanistically elegant hypothesis—although it awaits confirmation in controlled clinical trials.

Can CBD affect the growth of endometriotic tissue?

In addition to their analgesic effects, some preclinical studies suggest that cannabinoids may inhibit the growth of endometriosis lesions. Leconte et al. (2010) in a mouse model showed that WIN55,212-2 (a CB1 and CB2 agonist) inhibited endometriotic cell proliferation in vivo. Similar effects were observed with PEA and OEA, endogenous compounds similar to CBD. The question of whether pure CBD has the same properties at clinical doses remains open.

This doesn't mean that CBD is an "anti-endometriosis therapy"—such a claim goes far beyond the available data. However, these studies suggest that CBD may impact the disease more deeply than just pain symptoms. This is one area where future clinical RCTs could yield the most groundbreaking results. For now, it's worth considering CBD as a pain support with potentially additional biological justification, not as a proven disease-modifying therapy.

What do the ESHRE guidelines say about cannabinoids in endometriosis?

The European Society of Human Reproduction and Embryology (ESHRE) publishes regular guidelines on endometriosis, which serve as a reference for gynecologists in Poland and across Europe. The 2022 ESHRE guidelines on endometriosis discuss cannabinoids in the section on pain, acknowledging that current data are insufficient for formal clinical recommendations, but that the topic holds sufficient promise for further research.

Specifically, ESHRE does not recommend cannabinoids as first-line treatment for endometriosis, but does not discourage their use as an adjunct. This is an "insufficient evidence, but promising" position—which, given such a difficult-to-treat condition as endometriosis, is important information for patients. In practice, this means that a gynecologist should not discourage CBD from a patient seeking adjunctive pain management, provided there are no contraindications and appropriate supervision is in place. The ESHRE guidelines are available at eshre.eu.

CBD for menstrual pain and dysmenorrhea in endometriosis

Period pain (dysmenorrhea) is one of the most severe symptoms of endometriosis—often described as a "10/10 on the pain scale" and unresponsive to standard NSAIDs. For primary dysmenorrhea (without endometriosis), CBD has relatively good data from pilot studies. For secondary dysmenorrhea associated with endometriosis, there are fewer specific studies, but the mechanism of action is consistent.

CBD inhibits prostaglandin synthesis via an ibuprofen-like mechanism (COX-2 inhibition), reduces central pain sensitization via 5-HT1A, and modulates TRPV1. Related article on menstrual pain — CBD for Menstrual Pain — contains more information about dysmenorrhea that is directly relevant to women with endometriosis and menstrual pain.

Our observations: In support groups for women with endometriosis, CBD appears as one of the most frequently tested non-hormonal remedies. The most common pattern in descriptions: a consistent CBD dosage throughout the cycle for general inflammation control, plus an increased dose during menstrual periods. Crucially, women rarely switch from hormonal medications to CBD—rather, they add it as an additional tool when hormone therapy doesn't provide full pain control.

CBD Interactions with Endometriosis Drugs

Endometriosis is treated with a variety of hormonal and symptomatic medications – it’s worth knowing the potential interactions with CBD before combining them.

Progestogens (norethindrone, dienogest, medroxyprogesterone): Some progestogens are metabolized by CYP3A4, an enzyme that CBD may inhibit at higher doses. Potential interaction: increased progestogen concentrations in the blood, which may increase side effects. Clinical data are scarce, but caution is warranted. Inform your gynecologist about CBD use in hormone therapy.

GnRH analogues (leuprorelin, nafarelin): There are no data on interactions with CBD. GnRH analogues have a different metabolic pathway; the risk of interactions is low but untested.

NSAIDs (ibuprofen, naproxen, diclofenac): There are no clinically confirmed interactions with CBD. There is a potentially additive anti-inflammatory effect (both inhibit COX-2, albeit by different mechanisms)—which may be beneficial for pain, but requires awareness. Don't take higher than recommended doses of NSAIDs, thinking that CBD will "compensate.".

Oxycodone and tramadol (for resistant pain): CBD may potentiate the effects of opioids through CYP2D6 inhibition and central effects. Close medical consultation and monitoring are required when using opioids.

CBD, Sleep, and Quality of Life in Endometriosis

The chronic pain that accompanies endometriosis often leads to sleep disturbances, anxiety, and low mood—creating a vicious cycle: pain → poor sleep → lower pain threshold → more severe pain. Breaking this cycle is one of the most important therapeutic goals for endometriosis.

CBD has been well-documented to improve sleep quality in chronic pain and stress. Overview Shannon et al. (Permanente Journal, 2019) A 72-patient study found that CBD at a dose of 25–75 mg/day reduced anxiety in 79% participants and improved sleep in 67%—in just the first month of use. In endometriosis, where fear of the next pain episode is a constant companion, improved sleep and reduced anxiety have a direct impact on the ability to function.

How to Dose CBD for Endometriosis - A Practical Protocol

The lack of official clinical guidelines for endometriosis and CBD doesn't mean there's a lack of sound advice. Here's a protocol based on data on CBD in chronic pain, pelvic inflammatory disease, and immunomodulation research. Each person responds differently, so the regimen involves gradually increasing the dose and monitoring over several weeks:

Starting dose (weeks 1–2): 10 mg of CBD in the evening for the first two weeks. Monitor for tolerance—drowsiness or dry mouth are mild, transient side effects.

Baseline dose (weeks 3+): 15–20 mg of CBD morning and evening (30–40 mg/day). 10% oil is 3–4 drops twice daily. Use continuously throughout your cycle—not just on pain days. CBD works by accumulating and regulating the endocannabinoid system, not as a temporary remedy.

On menstrual days: You can increase the dose to 50–60 mg/day. Take CBD with a meal containing fat – bioavailability increases up to 4-fold, meaning a stronger effect with the same number of drops (Birnbaum et al., Epilepsia, 2019).

Product form: Full-spectrum preferred over isolate—the entourage effect (synergistic cannabinoids + terpenes) may provide better inflammatory pain control. Beta-caryophyllene (a terpene present in full-spectrum) is a CB2 agonist and has anti-inflammatory effects on its own.

Route of administration: Apply the oil sublingually for rapid absorption (15–45 minutes). For pelvic pain, topical use may also be considered—CBD oil applied topically to the lower abdomen may provide local relief through the skin (acting via TRPV1 in cutaneous nerves), although penetration through the abdominal wall into deeper tissues is limited.

For a detailed CBD dosing guide, please see the article Dosing CBD — how many drops to take.

Frequently Asked Questions

Does CBD help with endometriosis pain?

CBD has anti-inflammatory effects and modulates TRPV1 and CB2 pain receptors present in endometriotic tissue. A survey by Armour et al. (2019) found that women with endometriosis rated cannabinoids highly for relieving pelvic pain and dysmenorrhea. CBD does not cure endometriosis but may be a valuable adjunct to pain management.

How much CBD should I take for endometriosis?

The recommended dose range is 20–40 mg/day on days without severe pain, with the potential to increase to 50–60 mg on menstrual days. Use continuously throughout your cycle—CBD works by accumulating in the endocannabinoid system, not as a temporary remedy. 10% oil provides 5 mg/drop for convenient dosing.

Does CBD cure endometriosis?

No. CBD does not clinically prove to eliminate endometriosis lesions or inhibit their growth. It is a tool for pain and inflammation management—not a substitute for gynecological diagnosis or treatment (hormone therapy, surgery).

Can CBD be taken with hormone therapy for endometriosis?

CBD may interact with medications metabolized by CYP3A4, including some progestogens. Consult a gynecologist before combining CBD with hormone therapy. Inform your doctor about CBD and monitor for any changes in the side effects of your hormonal medications.

Does cannabidiol reduce pelvic pain?

Mechanistically, CBD blocks TRPV1 and CB2 activity in pelvic tissue, inhibiting nociception and inflammation. A study by Armour et al. (2019) indicates that women with endometriosis rate cannabinoids as more effective for pelvic pain than many other non-hormonal treatments. Clinical trials of CBD for pelvic pain are ongoing, but results are not yet available.

This article is for informational and educational purposes only and does not constitute medical advice. Before starting to use cannabis or CBD for therapeutic purposes, consult with a physician, especially if you are taking other medications, are pregnant, or breastfeeding.

Author: Michał Waluk · Published: 2026-05-04 · Updated: 2026-05-04